Lakefront Biotherapeutics (LKFT) Interest Expenses (2016 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Interest Expenses of -$160392.2 for Q1 2026, up 80.45% year-over-year from -$88884.0 in Q1 2025, and down 104.5% quarter-over-quarter from $3.6 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Interest Expenses (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Interest Expenses for 11 consecutive years, with -$160392.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 80.45% year-over-year to -$160392.2; the TTM figure through Mar 2026 stood at $1.3 million (up 109.21% YoY), while the FY2025 annual figure was $1.2 million, up 23.5% from the prior year.
- Interest Expenses slipped to -$160392.2 in Q1 2026 per LKFT's latest filing, from $3.6 million in the prior quarter.
- Across five years, Interest Expenses topped out at $26.1 million in Q4 2022 and bottomed at -$4.7 million in Q1 2022.
- Historically, Interest Expenses has averaged $1.7 million across 5 years, with a median of -$160392.2 in 2026.
- On a YoY basis, Interest Expenses climbed as much as 122.0% in 2025 and fell as far as 328.19% in 2025.
- Lakefront Biotherapeutics' Interest Expenses stood at $26.1 million in 2022, then tumbled by 88.33% to $3.0 million in 2023, then tumbled by 47.18% to $1.6 million in 2024, then surged by 122.0% to $3.6 million in 2025, then plunged by 104.5% to -$160392.2 in 2026.
- Business Quant data shows LKFT's Interest Expenses at -$160392.2 in Q1 2026, $3.6 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | -160,392.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -160,392.15 |
| Mar 31, 2026 | -160,392.15 |
| Dec 31, 2025 | 3.57 Mn |
| Dec 31, 2025 | 3.57 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Jun 30, 2025 | 579,563.36 |
| Jun 30, 2025 | 579,563.36 |
| Mar 31, 2025 | -820,469.86 |
| Mar 31, 2025 | -820,469.86 |
| Dec 31, 2024 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | -636,967.31 |
| Sep 30, 2024 | -636,967.31 |
| Jun 30, 2024 | 452,292.78 |
| Jun 30, 2024 | 452,292.78 |
| Mar 31, 2024 | -469,308.28 |
| Mar 31, 2024 | -469,308.28 |
| Dec 31, 2023 | 3.04 Mn |
| Dec 31, 2023 | 3.04 Mn |